News

Working in biotechnology means working to improve the planet and people’s lives

Published: 27th May 2021
Ion Arocena, CEO of AseBio, has delivered a speech at an event organised as part of the agreement that 3P Biopharmaceuticals has signed with the School of Pharmacy and Nutrition of the University of Navarra to promote training in Biotechnology
Read more

The University of Navarra and the company 3P Biopharmaceuticals will promote research and talent management in technology and the production of new drugs.

Published: 16th March 2021
This collaboration agreement aims to reinforce the figure of the pharmacist and other health science professionals as expert scientists, to collaborate with the academic world in developing industrial knowledge and drug manufacturing, and to promote their training.
Read more

3P Biopharmaceuticals and Invizius hope for reducing the cardiovascular complications associated with dialysis

Published: 26th November 2020
Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease
Read more

3P Biopharmaceuticals and SpyBiotech enter into a Vaccine cGMP Manufacturing Agreement

Published: 27th October 2020
3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases
Read more

3P Biopharmaceuticals appoints Iker Portugal as Chief Financial Officer

Published: 20th July 2020
3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer.
Read more

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

Published: 22nd June 2020
3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish Biotech company, have initiated a collaboration on innovative treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

Published: 24th April 2020
3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
Read more

STATEMENT: 3P Biopharmaceuticals shows its commitment against Covid-19

Published: 25th March 2020
We are living in difficult times due to the COVID19 pandemic, and it is in these times of serious difficulty that 3P Biopharmaceuticals shows its maximum commitment to its employees and to society.
Read more

3P Biopharmaceuticals joins International Day of Women and Girls in Science

Published: 11th February 2020
At 3P Biopharmaceuticals we celebrate the International Day of Women and Girls in Science, and we want to do so by appreciating and thanking each of the women that forms part of the 3P team
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.